4D Molecular Therapeutics, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Financial statements are unaudited. 4DMT is a clinical-stage gene therapy company developing AAV-vector product candidates; it has no approved products and has generated no product-sales revenue.
Key financial metrics
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $0.2 million | $14.6 million | $1.4 million | $16.6 million |
| Research and development expense | $20.4 million | $15.2 million | $39.8 million | $28.0 million |
| General and administrative expense | $8.2 million | $7.0 million | $16.4 million | $12.5 million |
| Net loss | $28.1 million | $7.6 million | $54.4 million | $24.0 million |
| Net loss per share | $0.87 | $0.28 | $1.69 | $0.90 |
| Operating cash used | — | $43.5 million | $31.6 million |
At June 30, 2022, cash and cash equivalents were $113.5 million and marketable securities were $148.1 million, totaling $261.6 million. Total assets were $302.9 million; total liabilities were $30.4 million, including $17.0 million of operating lease liabilities. The filing reports no borrowings. Accumulated deficit was $261.4 million. Gross margin is not reported; given the company’s development-stage operations and minimal collaboration revenue, it is not a meaningful indicator here.
Six-month investing cash flow was positive $3.4 million, reflecting $77.7 million of security maturities, offset by $65.9 million of purchases and $8.5 million of property and equipment purchases. Financing cash flow was positive $0.6 million. Cash and cash equivalents declined $39.5 million in the period.
Material changes versus the prior comparable period
- Revenue fell 99% in Q2 and 92% for the first half, principally because Roche terminated its collaboration agreement effective September 2021. Roche contributed $14.3 million of Q2 2021 revenue and $15.9 million of first-half 2021 revenue; no Roche revenue was recognized in 2022.
- Revenue in 2022 was primarily from uniQure: $0.2 million in Q2 and $1.4 million for the first half. The company recognized a $1.3 million increase in first-half uniQure revenue due to a reduction in estimated remaining costs for the performance obligation.
- Operating expenses increased 29% in Q2 and 39% for the first half. R&D growth reflected higher staffing and clinical-trial and consumables costs, including progression of the 4D-150 and 4D-710 trials; G&A growth was mainly personnel and outside-service costs.
- Net loss more than tripled in Q2 and more than doubled for the first half. The company attributes the broader trend to higher development spending alongside the loss of Roche collaboration revenue.
Outlook, risks and notable items
- Management expects operating losses and negative operating cash flows to continue, with R&D and G&A expenses expected to rise. The company expects 2022 collaboration revenue primarily from uniQure; it gives no specific revenue or earnings guidance.
- Management believes cash, cash equivalents and marketable securities will fund planned operations for at least one year from the filing’s issuance date. It expects to need substantial additional capital; no external funding is committed. Financing may be unavailable or dilutive, and a shortfall could force delays, reductions or termination of programs.
- Five candidates were in Phase 1/2 trials: 4D-310 (Fabry disease), 4D-150 (wet AMD), 4D-125 (XLRP), 4D-110 (choroideremia) and 4D-710 (cystic fibrosis). Clinical success, regulatory approval and commercialization remain uncertain.
- Key risks include gene-therapy safety and regulatory uncertainty, trial enrollment and timing, manufacturing scale-up and supplier dependence, competition, intellectual-property challenges, and COVID-19 and macroeconomic disruption. Management said it did not expect the Ukraine conflict to have a significant direct financial effect at the time of filing, but noted potential indirect risks.
- Available-for-sale securities had $1.8 million of accumulated unrealized losses at June 30, 2022; the company reported no other-than-temporary impairment. No material legal proceedings were outstanding. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported for the quarter.
Investor verification priorities
- Confirm the company’s cash runway against actual clinical, manufacturing and capital-spending plans, and monitor the timing and terms of any financing.
- Track clinical progress, safety, enrollment and readouts for the five Phase 1/2 programs, including any changes to timelines or trial plans.
- Review uniQure revenue recognition assumptions and remaining performance obligations, and assess the impact of Roche’s termination and any potential future partner arrangements.
- Monitor R&D spending, operating cash burn, capital expenditures and lease commitments as programs and internal manufacturing capabilities advance.
- Assess marketable-security valuation and interest-rate exposure, as well as the development, regulatory, manufacturing and intellectual-property risks disclosed in the filing.